In a further study of 49 aHCC tumour biopsies, the high expression of CD38 on immune cells was also associated with increased response to ICI (43.5% ORR high proportion of CD38+ cells vs. 3.9% low proportion, p = 0.019) and improved survival (mPFS 8.21 months vs. 1.64 months, p = 0.0065 and mOS 19.06 months vs. 9.59 months, p = 0.0295 for high expression of CD38 vs. low expression, respectively) [104]. Here, CD38 is linked to neoplasm.